NCT01196390
Clinical Trial Information
Trial Number: NCT01196390 (ClinicalTrials.gov)
Disease Type:
- Gastrointestinal Neoplasm - Gastroesophageal Cancer
Trial Title:
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Study ID:
RTOG-1010
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT01196390-D3 | This dataset, NCT01196390-D3, contains the treatment-related serious adverse event data presented in the RTOG-1010 primary publication (PMID: 35038433). NCT01196390-D1 contains the baseline, treatment, survival, and toxicity data. NCT01196390-D2 contains treatment-related adverse event data. |
| NCT01196390-D2 | This dataset, NCT01196390-D2, contains the treatment-related adverse event data presented in the RTOG-1010 primary publication (PMID: 35038433). NCT01196390-D1 contains the baseline, treatment, survival, and toxicity data. NCT01196390-D3 contains treatment-related serious adverse event data. |
| NCT01196390-D1 | This dataset, NCT01196390-D1, contains the baseline, treatment, survival, and toxicity data presented in the RTOG-1010 primary publication (PMID: 35038433). NCT01196390-D2 contains treatment-related adverse event data. NCT01196390-D3 contains treatment-related serious adverse event data. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®